France-based Cardiologs Technologies has secured an approval from the US Food and Drug Administration (FDA) for its Cardiologs ECG Analysis Platform, a cloud-based cardiac monitoring-analysis web service powered by artificial intelligence (AI).

The Cardiologs system is designed to help physicians in screening atrial fibrillation (AFib) and other arrhythmias using long-term ambulatory ECG monitoring recordings.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is also developed to recognise patterns in a cardiac signal for quick and precise analysis of arrhythmias, including AFib, in a similar intuitive manner as expert cardiologists.

CardiologsTechnologies noted that AFib is the most common human arrhythmia, affecting around 33 million patients across the globe.

AFib is also a growing problem in cardiovascular disease and is associated with an increased risk of severe stroke, heart failure and death. AFib is often asymptomatic, with stroke as the first manifestation.

See Also:

"It is especially powerful for long-term recordings that used to require a very laborious manual analysis process."

Various recent stroke registries have pointed out that AFib is linked with one-third of all ischemic strokes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cardiologs Technologies co-founder and CEO Yann Fleureau said: “Cardiologs is a game-changer for arrhythmia screening.

“A cardiologist recovers a digital ECG from any compatible cardiac monitoring device – such as a Holter monitor, smartwatch, ECG patch or even a connected t-shirt – then uploads it to the Cardiologs cloud and is able to immediately leverage our technology to identify relevant events.

“It is especially powerful for long-term recordings that used to require a very laborious manual analysis process.”

So far, Cardiologs Technologies has trained a neural network using more than 500,000 recordings.